Tom Wimbiscus
Shareholder
McAndrews
Edward Angelini
Associate General Counsel
Amneal Pharmaceuticals
Biopharma's AI transformation isn't being held back by algorithms, but by data infrastructure. In this fireside chat, Yves Fomekong Nanfack moderates a discussion between Jim Villa, Global Head of Research Strategy & Operations at Takeda, and Patrick Grady, CEO of TetraScience, exploring how leading organizations are building AI-native scientific data ecosystems that enable transformational outcomes at scale.
As the founding member of TetraScience's Scientific AI Lighthouse (SAIL) program, Takeda is pioneering a new approach to scientific data infrastructure, one designed to increase PTRS, accelerate time to IND submission, and industrialize around 200 scientific use cases across the value chain.
Drawing on real-world deployments that have already achieved 70% reductions in clone selection time, $34 million in annual savings from media optimization, and 75% fewer chromatography deviations, this conversation examines what it really takes to move from pilot to production at scale.
This conversation brings together strategic operations leadership, AI/ML research, and platform technology to explore not just what's possible, but what's working and what it takes to move from aspiration to execution.
Moderator
Yves Fomekong Nanfack
Head of AI/ML Research
Takeda
Patrick Grady
CEO
TetraScience
Patrick serves as co-founder, chairman, and CEO of TetraScience. Prior to TetraScience, Patrick spent three decades building, backing, and scaling market-defining companies and technology stacks within the high-performance computing, SaaS, cloud, and AI markets.
Patrick was the founder, CEO, and CTO of the first intelligent agent company of the Internet era, built one of the world’s first three SaaS companies, the first enterprise SaaS business, one of the first ten global technology unicorns, and the first AI unicorn.
To deliver these AI agents to market, Patrick played a well-documented role in pioneering and/or commercializing several enabling technologies, including web services, SOA, and multi-tenancy, which now undergird the trillion-dollar cloud market.
Recognized as a leading innovator by numerous publications and peer groups over the years, Patrick was a recipient of the 2006 Fast Company award, given to the top 50 people in the world most likely to change the way we live and work for his seminal efforts in personal agent AI.
Jim Villa
Global Head, Research Strategy & Operations
Takeda
TetraScience
Website: https://www.tetrascience.com/
TetraScience is the Scientific Data and AI Company. Its Scientific Data Foundry converts the “raw materials” of science into AI-native data, while its Scientific Use Case Factory industrializes AI-enabled workflows across R&D and manufacturing. Tetra AI connects the Foundry and Factory, providing agentic capabilities that guide scientists through complex workflows, surface cross-domain insights, and accelerate scientific outcomes. TetraScience is replatforming the world’s scientific industries for the AI era.
Learn how to transform raw data into actionable insights through effective data strategy, integration, and governance to fuel AI innovation in pharma.
Rameez Chatni
Global Director, AI Solutions, Pharmaceutical & Life Sciences
Cloudera
Cloudera
Website: https://www.cloudera.com/
Cloudera is a hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, enabling customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world’s largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what once seemed impossible—today and in the future.
Alexander Horspool
Associate Director, Innovation, Biotherapeutics Discovery
Boehringer Ingelheim
Wolfgang Colsman
Founder & CEO
ZONTAL
With nearly 30 years of visionary leadership, Wolfgang Colsman serves as the Chief Executive Officer of ZONTAL, a pioneering enterprise platform transforming the way organizations manage and preserve their digital information. Under his leadership, ZONTAL has become a catalyst for change across industries, redefining how data is captured, connected, and safeguarded for long-term value.
Before founding ZONTAL, Wolfgang spent over two decades at OSTHUS as Chief Innovation Officer and Chief Technology Officer, where he guided large-scale digital transformation initiatives. His ability to bridge cutting-edge technology with real-world business needs helped establish OSTHUS as a trusted, vendor-agnostic partner driving innovation for global enterprises.
Beyond his corporate achievements, Wolfgang has left a lasting mark on the life sciences and technology ecosystems through his leadership at the Allotrope Foundation and the Pistoia Alliance Methods Hub project. By championing data standards, interoperability, and collaborative infrastructures, he has empowered industries to break down silos, accelerate discovery, and unlock new opportunities for digital transformation. These efforts continue to shape how organizations think about data as a strategic asset rather than a byproduct.
Recognized for his ability to anticipate technological shifts and inspire collaborative progress, Wolfgang has become a respected voice in the digital landscape—bringing together vision, strategy, and execution to create sustainable impact.
ZONTAL
Website: https://zontal.io/
ZONTAL provides the premier data platform tailored for the life science industry. Our platform is at the forefront of digital transformation, delivering innovative solutions that address the intricate challenges faced by large-scale enterprises. Our services streamline IT processes, facilitate the integration of AI/ML applications, accelerate product time-to-market, and enhance regulatory compliance.
With a global presence encompassing the US, Europe, and Asia, ZONTAL is well positioned to offer seamless support to our clients worldwide. Our network of dedicated integration and service partners enables us to deliver our expertise and solutions in any country and across all time zones, ensuring our customers receive unparalleled support wherever they are.
The idea of a “one-click” Biologics License Application (BLA) has become the ultimate benchmark for what AI could enable in drug development — a world where data moves seamlessly from discovery to submission, with every result, dataset, and citation verified, traceable, and regulator-ready. But how far are we actually from that reality?
This session explores the technologies, infrastructures, and cultural shifts needed to bring automation to one of the most complex and high-stakes processes in life sciences: regulatory submission. The discussion will cut through the hype to define what “submission-grade AI” really means, the challenges that still stand in the way of full automation, and what it will take to build the regulatory trust required to get there.
Join us as we examine the future of AI-driven submissions — and ask the provocative question: could the next BLA really be submitted with a single click?
Farouk Daher
Head of Operations
Bluenote
Subha Madhavan
Vice President & Head of Clinical AI / ML
Pfizer
Dr. Eliezer Katz
CMO
Eledon Pharmaceuticals
Dr. Katz is an experienced transplant surgeon and a leader in clinical development in the pharmaceutical industry. Currently, Dr. Katz is the chief medical officer of Eledon Pharmaceutical. Before joining Eledon, Dr. Katz was CMO of eGenesis, a company in the xenotransplantation field. Previously, Dr. Katz served as Vice President and clinical development lead at Viela Bio and Horizon Therapeutics, where he was responsible for developing novel medications for autoimmune-related diseases and organ transplantation.
Dr. Katz earned his MD degree from the Hebrew University-Hadassah Medical School in Jerusalem, Israel.
Dr. Katz joined Viela Bio/Horizon following 30 years of combined academic and pharmaceutical career in the areas of organ transplantation, immunology, and immune-induced diseases.
His academic career as a transplant surgeon spanned 20 years, including directorship of two transplantation programs. The director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. During his tenure as a transplant surgeon, Dr. Katz implemented techniques for split liver and living donor liver transplantation, was actively involved in policy making related to organ donation and allocation and led efforts to increase organ donation.
After joining the pharmaceutical industry, Dr. Katz served as the vice president at CTI clinical trial and consulting services, as senior director in transplantation at Medicine Development Group, Pfizer Inc., and at Medimmune/AstraZeneca as a senior director at RIA (respiratory, inflammation, and autoimmunity), where he oversaw clinical development in neuro-inflammation, inflammatory bowel disease, and myositis.
Dr. Katz is an author of more than 60 peer-reviewed publications.
Reed Few
Director of Data Science & External Innovation
J&J
Reed Few is Director of External Innovation for Data Science and Digital Health at Johnson and Johnson Innovative Medicine, R&D. With a background spanning real-world data, predictive modeling, and precision medicine, Reed is passionate about finding ways to combine data and AI to bring therapies from concept to approval, faster. In her current role, she looks for partnerships that will help to design better, more diverse clinical trials, improve operational efficiencies, and find digital endpoints that better reflect how patients live and feel in the real world. As of late, her focus has been on initiatives applying generative AI and large language models to accelerate document creation across preclinical, CMC, and clinical domains – advancing smarter, faster, and more connected drug development.
Bluenote
Website: https://www.bluenotehealth.com/
Bluenote helps scientists, researchers, and medical writers accelerate critical workflows by 50–75%—so you can spend less time on paperwork and more time advancing life-saving therapies.
Learn how scalable, cloud-based AI infrastructure accelerates model training, data integration, and collaborative research across global drug discovery teams.
Kevin Cochrane
Chief Marketing Officer
Vultr
Kevin is a 25+ year pioneer of the digital experience space. Now at Vultr, Kevin is now working to build Vultr's global brand presence as a leader in the independent Cloud platform market.
Vultr
Website: https://www.vultr.com/
Vultr, founded in 2014, is on a mission to empower developers and businesses by simplifying the deployment of infrastructure via its advanced cloud platform. Vultr is strategically located in 32 data centers around the globe and provides frictionless provisioning of Cloud Compute, Cloud GPU, Cloud Storage, Networking, and Bare Metal.
- Explore practical strategies for building high-quality, diverse datasets that reduce bias and improve model performance across drug discovery pipelines.
Nevin Gerek Ince
Director, Data & Solutions Engineering
Novo Nordisk